Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with locally advanced or metastatic (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment~* Easter Cooperative Oncology Group (ECOG) performance status 0 to 2~* Estimated life expectancy of at least 8 weeks~Exclusion Criteria:~* Known or suspected brain metastases~* Concurrent administration of any other tumor therapy~* Serious concomitant disorders~* Pregnancy or breast feeding~* Inability or unwillingness to take folic acid or vitamin B12 supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pemetrexed plus carboplatin (Type: EXPERIMENTAL): Drug: pemetrexed 500 milligrams per square meter (mg/m\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram\*minute/milliLiter (mg\*min/mL), IV, q 21 days x 6 cycles maximum
- docetaxel plus carboplatin (Type: ACTIVE_COMPARATOR): Drug: docetaxel 75 mg/m\^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

Based on this trial design, predict the completion outcome and termination type (if applicable).